Efficacy and Safety of Taspoglutide in Patients with Type 2 Diabetes Inadequately Controlled with Metformin Plus Pioglitazone over 24 Weeks: T-Emerge 3 Trial

Robert R. Henry; Sunder Mudaliar; Linda Kanitra; Michael Woloschak; Raffaella Balena

首页> 外文期刊>The journal of clinical endocrinology and metabolism >Efficacy and Safety of Taspoglutide in Patients with Type 2 Diabetes Inadequately Controlled with Metformin Plus Pioglitazone over 24 Weeks: T-Emerge 3 Trial

【24h】

Efficacy and Safety of Taspoglutide in Patients with Type 2 Diabetes Inadequately Controlled with Metformin Plus Pioglitazone over 24 Weeks: T-Emerge 3 Trial

机译：Taspoglutide在2型糖尿病患者中的疗效和安全性与二甲双胍加上吡格列酮在24周内患者不足：T-Emerge 3试验

获取原文

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Objective:This study assessed the efficacy and safety of once-weekly taspoglutide in patients with type 2 diabetes mellitus inadequately controlled with metformin plus pioglitazone compared with placebo.

机译：目的：本研究评估了与安慰剂相比，用二甲双胍加上吡酰基患者对2型糖尿病患者进行一次每周Taskoglutide的疗效和安全性。

著录项

来源
《The journal of clinical endocrinology and metabolism》 |2012年第7期|共10页
作者
Robert R. Henry; Sunder Mudaliar; Linda Kanitra; Michael Woloschak; Raffaella Balena;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种
中图分类
关键词

相似文献

外文文献
中文文献
专利

1. Efficacy and safety of taspoglutide monotherapy in drug-naive type 2 diabetic patients after 24 weeks of treatment: Results of a randomized, double-blind, placebo-controlled phase 3 study (T-emerge 1) [J] . RazI., HoekstraJ., FonsecaV., Diabetes care . 2012,第3期

机译：Taspoglutide单药治疗24周后未接受过药物治疗的2型糖尿病患者的疗效和安全性：一项随机，双盲，安慰剂对照的3期研究的结果（T出现1）
2. Efficacy and tolerability of taspoglutide versus pioglitazone in subjects with type 2 diabetes uncontrolled with sulphonylurea or sulphonylurea-metformin therapy: A randomized, double-blind study (T-emerge 6) [J] . Diabetes, obesity & metabolism . 2013,第3期

机译：taspoglutide与吡格列酮对2型糖尿病患者的磺脲或磺脲二甲双胍治疗无法控制的疗效和耐受性：一项随机，双盲研究（T出现6）
3. Efficacy and safety of once-weekly glucagon-like peptide 1 receptor agonist albiglutide (HARMONY 1 trial): 52-week primary endpoint results from a randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes mellitus not controlled on pioglitazone, with or without metformin [J] . Reusch J., Stewart M. W., Perkins C. M., Diabetes, obesity & metabolism . 2014,第12期

机译：每周一次的胰高血糖素样肽1受体激动剂阿比鲁肽的有效性和安全性（HARMONY 1试验）：52周主要终点来自一项随机，双盲，安慰剂对照试验，该试验针对不受吡格列酮控制的2型糖尿病患者，有或没有二甲双胍
4. Controlled Release of Metformin Loaded Polyvinyl Alcohol (PVA) Microbubble/Nanoparticles Using Microfluidic Device for the Treatment of Type 2 Diabetes Mellitus [C] . Sumeyye Cesur, Muhammet Emin Cam, Fatih Serdar Sayin, International work-conference on bioinformatics and biomedical engineering . 2020

机译：使用微流体装置控制二甲双胍负载的聚乙烯醇（PVA）微泡/纳米颗粒的控释，用于治疗2型糖尿病
5. A randomized placebo-controlled trial of pioglitazone to improve metabolic control in adolescents with type 1 diabetes mellitus. [D] . Zdravkovic, Vera. 2005

机译：吡格列酮对改善1型糖尿病青少年的代谢控制的随机安慰剂对照试验。
6. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin compared with alpha-glucosidase inhibitor in Japanese patients with type 2 diabetes inadequately controlled on metformin or pioglitazone alone (Study for an Ultimate Combination Therapy to Control Diabetes with Sitagliptin-1): A multicenter randomized open-label non-inferiority trial [O] . Hidetaka Yokoh, Kazuki Kobayashi, Yasunori Sato, 2015

机译：在单独使用二甲双胍或吡格列酮控制不充分的日本2型糖尿病患者中二肽基肽酶4抑制剂西他列汀与α-葡萄糖苷酶抑制剂相比的疗效和安全性（采用西他列汀1控制糖尿病的最终联合疗法研究）：随机开放标签非劣效性试验
7. Efficacy and Safety of Lixisenatide Once Daily Versus Exenatide Twice Daily in Type 2 Diabetes Inadequately Controlled on Metformin: A 24-week, randomized, open-label, active-controlled study (GetGoal-X) [O] . J. Rosenstock, D. Raccah, L. Koranyi, 2013

机译：Lixisenatide每日疗效和安全性与丁肽每天两次在二甲双胍上不充分控制的2型糖尿病：24周，随机，开放标签，主动控制的研究（GetGoal-X）

Efficacy and Safety of Taspoglutide in Patients with Type 2 Diabetes Inadequately Controlled with Metformin Plus Pioglitazone over 24 Weeks: T-Emerge 3 Trial

摘要

著录项

相似文献

相关主题

期刊订阅